Microbiome, Autoimmune Diseases and HIV Infection: Friends or Foes?

Pellicano, Chiara; Leodori, Giorgia; Innocenti, Giuseppe Pietro; Gigante, Antonietta; Rosato, Edoardo

doi:10.3390/nu11112629

Cited by 5 publications

(4 citation statements)

References 185 publications

(252 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study had prominent strengths. The microbiota dysbiosis in HIV-infected individuals has been reported in several studies, [47][48][49][50][51][52] whereas the relationship of immunological nonresponse and gut microbiota has not been elucidated. Our study is one of the first studies to compare the gut microbiota between HIV-infected MSM with poor immunological response and good immunological response using 16S rRNA sequencing.…”

Section: Discussionmentioning

confidence: 99%

Altered gut microbiota is associated with different immunologic responses to antiretroviral therapy in HIV‐infected men who have sex with men

Zhao

Feng

Luo

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

The association between gut microbiota and immunologic nonresponse among people living with HIV (PLHIV) on antiretroviral therapy (ART) is not well documented. This study aimed to characterize gut microbiota among HIV-infected men who have sex with men (MSM) with different immunologic responses. We recruited HIV-infected MSM and HIV-uninfected MSM (healthy controls, HC) in Guangzhou, June-October 2021. HIV-infected MSM were grouped into good immunological responders (GIR) (CD4 + T cell count ≥ 350 cells/μL) and poor immunological responders (PIR) (<350 cells/μL). Blood and stool samples were collected. Microbial translocation in serum was performed using enzyme-linked immunosorbent assay (ELISA). Bacterial 16S ribosomal DNA sequencing was performed on stool samples, and microbial metabolites were obtained through gas chromatography-mass spectrometry. 56 GIR, 41 PIR, and 51 HC were included. Microbial translocation marker soluble cluster of differentiation 14 (sCD14) in both GIR and PIR groups was significantly higher than that in HC. Compared with PIR or HC groups, the genera of Coprococcus, Blautia, Clostridium, and SMB53 were decreased, whereas Megamonas and Megasphaera were more abundant in GIR group. Compared with GIR or PIR groups, Bifidobacterium, Collinsella, Faecalibacterium, Oscillospira, and Roseburia were more abundant, whereas

show abstract

Section: Discussionmentioning

confidence: 99%

Altered gut microbiota is associated with different immunologic responses to antiretroviral therapy in HIV‐infected men who have sex with men

Zhao

Feng

Luo

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Most SSc patients present gastrointestinal tract dysfunction and dysbiosis (altered gut microbiota composition) [ 37 ]. Paraprobiotics and postbiotics play a proactive role in the maintenance of eubiosis.…”

Section: Discussionmentioning

confidence: 99%

HIV-Associated Systemic Sclerosis: Literature Review and a Rare Case Report

Hasan

Aqil

Panigrahi

2022

IJERPH

View full text Add to dashboard Cite

Highly antiretroviral therapy (HAART) used in Human Immunodeficiency Virus (HIV) treatment may prolong the life span of people living with HIV/Acquired Immune Deficiency Syndrome (AIDS) but may also induce the onset of autoimmune disorders. However, HIV-associated systemic sclerosis (SSc) is an extremely rare occurrence, and only four case reports and two studies documenting this association have been reported to date. We report a rare case of HIV-associated SSc who was referred to us for pain management in her mandibular teeth. A 44-year-old female patient diagnosed with HIV-associated SSc reported a complaint of pain in the lower posterior teeth region. Physical examination revealed typical features of SSc. The pain in her mandibular teeth was due to food lodgement, and she was advised to use toothpaste with a powered toothbrush and mouth stretching exercises, followed by oral prophylaxis. The patient responded well to therapy. HIV-associated SSc is an extremely rare occurrence, with an obscure pathogenic mechanism of HIV-associated autoimmunity. Oral physicians play a crucial role in disease management and should be incorporated into the multidisciplinary team.

show abstract

“…People living with HIV (PLWH) show a higher risk of developing numerous chronic pathologies, such as autoimmune and tumoral diseases [ 6 , 7 , 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Loco-Regional Treatments for Hepatocellular Carcinoma in People Living with HIV

Micali

Russotto

Caci

et al. 2022

Infectious Disease Reports

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) accounts for approximately 75–90% of primary liver cancers and is the sixth most common cancer and the third leading cause of cancer-related deaths worldwide. In the HIV-positive population, the risk of HCC is approximately four times higher than in the general population, with higher cancer-specific mortality than in HIV-negative patients. In most cases, HCC diagnosis is made in patients younger than the HIV-negative population and in the intermediate-advanced stage, thus limiting the therapeutic possibilities. Treatment choice in HIV-positive patients with HCC is subject to cancer staging, liver function and health status, as for HIV-negative and non-HIV-negative HCC patients. There are relatively few studies on the efficacy and safety in HIV-positive patients to date in loco-regional treatments for HCC. So far, literature shows that curative treatments such as radiofrequency ablation (RFA) have no significant differences in overall survival between HIV-positive and HIV-negative patients, as opposed to palliative treatments such as TACE, where there is a significant difference in overall survival. Although it can be assumed that the most recently discovered loco-regional therapies are applicable to HIV-positive patients with HCC in the same way as HIV-negative patients, further studies are needed to confirm this hypothesis. The purpose of our review is to evaluate these treatments, their efficacy, effectiveness, safety and their applicability to HIV-positive patients.

show abstract

Microbiome, Autoimmune Diseases and HIV Infection: Friends or Foes?

Cited by 5 publications

References 185 publications

Altered gut microbiota is associated with different immunologic responses to antiretroviral therapy in HIV‐infected men who have sex with men

Altered gut microbiota is associated with different immunologic responses to antiretroviral therapy in HIV‐infected men who have sex with men

HIV-Associated Systemic Sclerosis: Literature Review and a Rare Case Report

Loco-Regional Treatments for Hepatocellular Carcinoma in People Living with HIV

Contact Info

Product

Resources

About